Elizabeth A. Szamreta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elizabeth A. Szamreta has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Emily Mulvihill
Oracle Life Sciences, Real World Evidence, Austin, TX, USA
3 shared publicationsMatthew Monberg
Merck & Co., Inc
3 shared publications- Matthew Monberg
Merck & Co., Inc., Rahway, USA
3 shared publications - Domenica Lorusso
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
2 shared publications - Karin Yamada
Merck & Co Inc, Rahway, NJ, USA
2 shared publications Katherine Aguinaga
Oracle Life Sciences, 2800 Rock Creek Pkwy, North Kansas City, MO 64117, USA
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Elsevier in Gynecologic Oncology
- Vol. 210, 1-9
Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III–IVA cervical cancer in the United States
- 19 May 2026
- Published by Elsevier in Gynecologic Oncology
- Vol. 210, 1-9
Open AccessCost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III–IVA cervical cancer in the United States
- Open Access
- 13 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1765220
Predicting platinum-resistance in advanced ovarian cancer: defining patient and disease characteristics to improve treatment approaches at initiation of treatment or earlier in the course of the disease
Introduction: This study aimed to describe differences in characteristics and outcomes between patients with platinum sensitive or platinum resistant advanced ovarian cancer in a community oncology setting. Methods: This was a retrospective study of adult patients with Stage III/IV ovarian cancer who received 4+ cycles of a front-line platinum-based regimen between 01/01/2017 and 06/30/2021 (followed until 12/31/2021) within The US Oncology Network. Platinum sensitive or resistant patients were included while refractory patients were excluded. Structured and chart review data were used. Multivariable logistic regression assessed factors associated with platinum sensitivity vs. resistance. Results: A total of 108 platinum sensitive and 34 resistant patient charts were reviewed. In addition to platinum-based chemotherapy, 19% of patients also initiated bevacizumab as part of their front-line regimen. Most patients were White (63%) and diagnosed at Stage IIIC (55%) or IV (33%). ECOG performance status scores were 0/1 for 47% and 2+ for 20% of patients while BRCA mutations were observed among 7.7%. Sensitive vs. resistant patients were younger (p=0.045) and fewer were obese (p=0.011). Stage IV disease (odds ratio [OR]=3.6, p=0.009) was associated with significantly higher odds of platinum resistance after front-line treatment compared to Stage III, while obesity (OR = 2.6, p=0.067) and ECOG 2+ (OR = 2.9, p=0.057) were non-significantly associated with higher odds of resistance. Median overall survival was not reached in sensitive patients, and was 16.7 months in resistant patients. Median progression-free survival in sensitive and resistant patients was 19.6 and 7.9 months, respectively. Discussion: When exploring factors associated with response to front-line platinum-based treatment of ovarian cancer, Stage IV disease was significantly associated with resistance. As platinum resistant patients have poorer survival and fewer treatment options, it is important to further define the biology and appropriate initial management of these patients.
- 13 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1765220
Open AccessPredicting platinum-resistance in advanced ovarian cancer: defining patient and disease characteristics to improve treatment approaches at initiation of treatment or earlier in the course of the disease
Introduction: This study aimed to describe differences in characteristics and outcomes between patients with platinum sensitive or platinum resistant advanced ovarian cancer in a community oncology setting. Methods: This was a retrospective study of adult patients with Stage III/IV ovarian cancer who received 4+ cycles of a front-line platinum-based regimen between 01/01/2017 and 06/30/2021 (followed until 12/31/2021) within The US Oncology Network. Platinum sensitive or resistant patients were included while refractory patients were excluded. Structured and chart review data were used. Multivariable logistic regression assessed factors associated with platinum sensitivity vs. resistance. Results: A total of 108 platinum sensitive and 34 resistant patient charts were reviewed. In addition to platinum-based chemotherapy, 19% of patients also initiated bevacizumab as part of their front-line regimen. Most patients were White (63%) and diagnosed at Stage IIIC (55%) or IV (33%). ECOG performance status scores were 0/1 for 47% and 2+ for 20% of patients while BRCA mutations were observed among 7.7%. Sensitive vs. resistant patients were younger (p=0.045) and fewer were obese (p=0.011). Stage IV disease (odds ratio [OR]=3.6, p=0.009) was associated with significantly higher odds of platinum resistance after front-line treatment compared to Stage III, while obesity (OR = 2.6, p=0.067) and ECOG 2+ (OR = 2.9, p=0.057) were non-significantly associated with higher odds of resistance. Median overall survival was not reached in sensitive patients, and was 16.7 months in resistant patients. Median progression-free survival in sensitive and resistant patients was 19.6 and 7.9 months, respectively. Discussion: When exploring factors associated with response to front-line platinum-based treatment of ovarian cancer, Stage IV disease was significantly associated with resistance. As platinum resistant patients have poorer survival and fewer treatment options, it is important to further define the biology and appropriate initial management of these patients.
- Open Access
- 1 July 2025
- Published by Elsevier in Gynecologic Oncology
- Vol. 199, 88-95
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer
- 1 July 2025
- Published by Elsevier in Gynecologic Oncology
- Vol. 199, 88-95
Open AccessPatient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer
- Open Access
- 3 May 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (7) , 101919
Oncologist perceptions of “cure” and long-term management in advanced ovarian cancer in the United States: results from a cross-sectional survey
- 3 May 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (7) , 101919
Open AccessOncologist perceptions of “cure” and long-term management in advanced ovarian cancer in the United States: results from a cross-sectional survey
- Open Access
- 22 April 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (4) , e0321654
Real-world evidence in gynecologic cancers presented at key oncology conferences in the United States: Distribution and factors related to high-tier acceptance
Purpose: To describe the distribution, trends, and characteristics of types of real-world evidence (RWE) abstracts presented at key oncology congresses. Methods: Data on gynecologic cancers (cervical, ovarian, endometrial, and multiple gynecologic/other) were extracted from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) conference databases (2018–2020) to: a) identify the proportion of clinical trial (CT) versus RWE abstracts accepted; b) describe the distribution and tier of acceptance of RWE versus CTs; c) analyze the characteristics (authorship, data source, data type, study design, outcome[s], and presence of statistically significant results) associated with RWE acceptance. Results: Of 3163 abstracts screened, 2271 (77% RWE, 23% CTs) were included. RWE represented a higher proportion of work at SGO versus ASCO (70% vs 30%). Overall, more RWE studies versus CTs were accepted as posters (75% vs 60%), while fewer were accepted as oral presentations (4% vs 20%; p < 0.001 for both). Among RWE abstracts, 90% had academic author(s), 68% of studies were from North America, 45% used other clinical data sources, and nearly 32% reported statistically significant results. Approximately 60% of RWE were retrospective and 9% were prospective. The most common outcomes in RWE abstracts were molecular analyses (18%) and survival based on treatment efficacy (13%; p < 0.001). Conclusion: RWE abstracts were accepted for presentation more frequently at SGO versus ASCO, and majority of them were presented as posters. While RWE abstracts are prevalent and provide valuable data for healthcare decision-making, they do not always achieve the visibility of CTs.
- 22 April 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (4) , e0321654
Open AccessReal-world evidence in gynecologic cancers presented at key oncology conferences in the United States: Distribution and factors related to high-tier acceptance
Purpose: To describe the distribution, trends, and characteristics of types of real-world evidence (RWE) abstracts presented at key oncology congresses. Methods: Data on gynecologic cancers (cervical, ovarian, endometrial, and multiple gynecologic/other) were extracted from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) conference databases (2018–2020) to: a) identify the proportion of clinical trial (CT) versus RWE abstracts accepted; b) describe the distribution and tier of acceptance of RWE versus CTs; c) analyze the characteristics (authorship, data source, data type, study design, outcome[s], and presence of statistically significant results) associated with RWE acceptance. Results: Of 3163 abstracts screened, 2271 (77% RWE, 23% CTs) were included. RWE represented a higher proportion of work at SGO versus ASCO (70% vs 30%). Overall, more RWE studies versus CTs were accepted as posters (75% vs 60%), while fewer were accepted as oral presentations (4% vs 20%; p < 0.001 for both). Among RWE abstracts, 90% had academic author(s), 68% of studies were from North America, 45% used other clinical data sources, and nearly 32% reported statistically significant results. Approximately 60% of RWE were retrospective and 9% were prospective. The most common outcomes in RWE abstracts were molecular analyses (18%) and survival based on treatment efficacy (13%; p < 0.001). Conclusion: RWE abstracts were accepted for presentation more frequently at SGO versus ASCO, and majority of them were presented as posters. While RWE abstracts are prevalent and provide valuable data for healthcare decision-making, they do not always achieve the visibility of CTs.
- 10 January 2024
- Published by Elsevier in Gynecologic Oncology
- Vol. 180, 170-177
Prognosis and conditional survival among women with newly diagnosed ovarian cancer
- 10 January 2024
- Published by Elsevier in Gynecologic Oncology
- Vol. 180, 170-177
Prognosis and conditional survival among women with newly diagnosed ovarian cancer
- Open Access
- 24 December 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 51, 101321
Information needs during cancer care: Qualitative research with locally advanced cervical cancer patients in Brazil, China, Germany, & the US
- 24 December 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 51, 101321
Open AccessInformation needs during cancer care: Qualitative research with locally advanced cervical cancer patients in Brazil, China, Germany, & the US
- 6 December 2023
- Published by Elsevier in Gynecologic Oncology
- Vol. 180, 79-85
Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting
- 6 December 2023
- Published by Elsevier in Gynecologic Oncology
- Vol. 180, 79-85
Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting
- Open Access
- 30 December 2022
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 63
Information needs during cancer care: qualitative research with advanced cervical cancer patients in Brazil, China, Germany, and the United States
- 30 December 2022
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 63
Open AccessInformation needs during cancer care: qualitative research with advanced cervical cancer patients in Brazil, China, Germany, and the United States
- 7 January 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 305 (6) , 1647-1654
Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer
Purpose We used real-world claims data to assess the utility of the relatively novel therapeutic bevacizumab in patients with newly diagnosed ovarian cancer in the United States after release of clinical data but prior to FDA approval. Methods We used the IQVIA Pharmetrics Plus commercial claims database to identify women with a new diagnosis of ovarian cancer who underwent primary surgery or neoadjuvant chemotherapy followed by interval surgery from 2006 to 2018. We calculated the rate of use of bevacizumab, and the relative frequency of hospital and emergency department (ED) admissions. Treatment-related toxicities, and time to second line chemotherapy were calculated. Results Among 8923 women who met study parameters, 533 (6.0%) received bevacizumab. The rate of use increased over time from 1.5% in 2006 to 7.0% in 2017 (P < 0.001), with a peak of 8.6% in 2011. The use was lowest in those ≥ 70 years old (2.8%), and in the West (4.5%), and was unaffected by number of comorbidities. Over one third (35.1%) received bevacizumab for less than 3 months, and 15.9% remained on it for greater than 13 months. Bevacizumab use was not associated with hospitalization or ED admission. Toxicities included hypertension (15.0%), kidney damage (6.8%), bleeding (3.8%), venous thrombo-embolism (2.3%) and fistula (1.1%). Time from initiation of first line chemotherapy to initiation of second line therapy was 19.9 months without bevacizumab and 22.6 months with bevacizumab use. Conclusions Real-world patterns of upfront bevacizumab use prior to FDA approval in 2018 differed significantly from trial data.
- 7 January 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 305 (6) , 1647-1654
Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer
Purpose We used real-world claims data to assess the utility of the relatively novel therapeutic bevacizumab in patients with newly diagnosed ovarian cancer in the United States after release of clinical data but prior to FDA approval. Methods We used the IQVIA Pharmetrics Plus commercial claims database to identify women with a new diagnosis of ovarian cancer who underwent primary surgery or neoadjuvant chemotherapy followed by interval surgery from 2006 to 2018. We calculated the rate of use of bevacizumab, and the relative frequency of hospital and emergency department (ED) admissions. Treatment-related toxicities, and time to second line chemotherapy were calculated. Results Among 8923 women who met study parameters, 533 (6.0%) received bevacizumab. The rate of use increased over time from 1.5% in 2006 to 7.0% in 2017 (P < 0.001), with a peak of 8.6% in 2011. The use was lowest in those ≥ 70 years old (2.8%), and in the West (4.5%), and was unaffected by number of comorbidities. Over one third (35.1%) received bevacizumab for less than 3 months, and 15.9% remained on it for greater than 13 months. Bevacizumab use was not associated with hospitalization or ED admission. Toxicities included hypertension (15.0%), kidney damage (6.8%), bleeding (3.8%), venous thrombo-embolism (2.3%) and fistula (1.1%). Time from initiation of first line chemotherapy to initiation of second line therapy was 19.9 months without bevacizumab and 22.6 months with bevacizumab use. Conclusions Real-world patterns of upfront bevacizumab use prior to FDA approval in 2018 differed significantly from trial data.